Email updates

Keep up to date with the latest news and content from Genome Biology and BioMed Central.

Research news

Loss of p16Ink4a

Jonathan B Weitzman

Genome Biology 2001, 2:spotlight-20010907-01  doi:10.1186/gb-spotlight-20010907-01

The electronic version of this article is the complete one and can be found online at:


Published:7 September 2001

© 2001 BioMed Central Ltd

Research news

The CDKN2A (INK4a/ARF) locus encodes two distinct cell cycle inhibitors, p16Ink4a and p19ARF, both of which have been implicated in tumorigenesis. In the September 6 Nature, two independent groups report the generation of knockout mice specifically lacking p16Ink4a. Surprisingly, mouse embryonic fibroblasts (MEFs) lacking p16Ink4a were normal in terms of growth characteristics, senescence phenotypes and resistance to oncogenic Ras-induced transformation. These observations are in contrast to results obtained with p19ARF-null fibroblasts. But both groups provide evidence for a role in tumour suppression: Krimpenfort et al. report that p16Ink4a mutation results in a susceptibility to spontaneous and carcinogen-induced melanoma formation (Nature 2001, 413:83-86). Sharpless et al. also found sarcomas, adenomas and lymphomas (Nature 2001, 413:86-91). These results establish that the CDKN2A locus does indeed contain two distinct tumour suppressor genes.

References

  1. The INK4A/ARF locus and its two gene products.

    PubMed Abstract | Publisher Full Text OpenURL

  2. [http://www.nature.com] webcite

    Nature

  3. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF.

    PubMed Abstract | Publisher Full Text OpenURL